Form: 8-K

Current report filing

September 2, 2004

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (date of earliest event reported): September 2, 2004

 

 

COMMONWEALTH BIOTECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

 

Virginia   001-13467   56-1641133

(State or Other Jurisdiction

of Incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

601 Biotech Drive

Richmond, Virginia 23235

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (804) 648-3820

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

 

As of August 30, 2004, Commonwealth Biotechnologies, Inc. (“CBI”) signed a distribution agreement with Fisher Scientific, Inc. (“FSI”) to distribute CBI’s services through FSI. Pursuant to this agreement, FSI shall qualify potential clients through their sales force on behalf of CBI. Additional details of the agreement and the prospective launch date will be announced in a future press release. Prior to the execution of this agreement, there was no prior relationship between CBI and FSI.

Pursuant to the requirement of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

COMMONWEALTH BIOTECHNOLOGIES, INC.

By:

  

/s/ Robert B. Harris, Ph.D.
    Robert B. Harris, Ph.D.
    President and Chief Executive Officer

 

Dated: September 2, 2004